SCHEMBL4891835

SCHEMBL4891835

Cc1ccccc1Nc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 8/20 0.69
PDE5A O76074 3/20 0.69
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
MAPT P10636 3/20 0.68
LMNA P02545 2/20 0.68
KDM4E B2RXH2 2/20 0.68
ALDH1A1 P00352 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
LATS1 O95835 1/20 0.67
TP53 P04637 1/20 0.65
POLB P06746 1/20 0.64
ABCB1 P08183 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107131 0.86 MEN1 (0.73) ABCG2PDE5AMEN1KMT2AMAPT
SCHEMBL2304172 0.82 KDM1A (0.65) ABCG2MEN1KMT2AMAPTLMNA
SCHEMBL4089757 0.82 CYP1A2 (0.67) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL1063734 0.82 MEN1 (0.76) ABCG2PDE5AMEN1KMT2AMAPT
SCHEMBL4085200 0.82 PDE5A (1.00) ABCG2PDE5AMEN1KMT2AMAPT
SCHEMBL9776700 0.81 SLC2A1 (0.83) MAPTLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL1056599 0.81 ABCG2 (1.00) ABCG2PDE5AMEN1KMT2AMAPT
SCHEMBL31375190 0.81 LATS1 (1.00) LMNAKDM4ELATS1POLB
SCHEMBL27400911 0.81 LATS1 (0.50) ABCG2PDE5AMEN1KMT2AMAPT
SCHEMBL26177128 0.81 LATS1 (1.00) LMNAKDM4ELATS1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R ABCG2 207/4885PDE5A 204/4885MEN1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.